Alma Bio Therapeutics welcomes Dr. Pierre A. Morgon as member of the board of directors

Dr. Morgon, a 30-year pharma industry veteran, will bring vast experience and business expertise to Alma as it progresses towards the clinical trial of a therapeutic drug to cure autoimmune diseases.

Lyon, France, September 26, 2017 – Alma Bio Therapeutics SAS (Alma), a pioneer of a new class of curative therapies that harnesses the patient’s own immune system to treat autoimmune diseases, announces today that Dr. Pierre A. Morgon will join its board of directors. He will take an active role in Alma’s Series A financing, which will commence
shortly.

​Alma has developed a therapeutic entity aimed at treating the underlying cause of uncontrolled inflammation in autoimmune diseases. While its therapeutic entity, a DNA plasmid, has shown strong potential for treating many autoimmune diseases, the company is targeting Crohn’s disease, one of the two major types of Inflammatory Bowel Disease (IBD), as its first clinical application. There are no available curative treatments for IBD, a chronic debilitating disease that affects the gastrointestinal tract.

Read More